These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21663950)

  • 1. SHARP: a stab in the right direction in chronic kidney disease.
    Stevens KK; Jardine AG
    Lancet; 2011 Jun; 377(9784):2153-4. PubMed ID: 21663950
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
    Green D; Panayotova R; Ritchie JP; O'Riordan E; McDonald J
    J Ren Care; 2012 Sep; 38(3):138-46. PubMed ID: 22613701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting.
    Friedman HS; Rajagopalan S; Barnes JP; Roseman H
    Clin Ther; 2011 Feb; 33(2):212-24. PubMed ID: 21497705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 7. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 8. Antioxidants for chronic kidney disease.
    Jun M
    Nephrology (Carlton); 2013 Aug; 18(8):576-8. PubMed ID: 23865542
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
    Almquist T; Jacobson SH; Mobarrez F; Näsman P; Hjemdahl P
    Eur J Clin Invest; 2014; 44(3):276-84. PubMed ID: 24720535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcific aortic stenosis.
    Pazianas M
    N Engl J Med; 2009 Jan; 360(1):85; author reply 85-6. PubMed ID: 19118311
    [No Abstract]   [Full Text] [Related]  

  • 11. [The SHARP study].
    Bianchi S; Gaspardone A
    G Ital Cardiol (Rome); 2013 Feb; 14(2):87-91. PubMed ID: 23389310
    [No Abstract]   [Full Text] [Related]  

  • 12. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids, inflammation, and chronic kidney disease: a SHARP perspective.
    Waters DD; Vogt L
    Kidney Int; 2018 Apr; 93(4):784-786. PubMed ID: 29571452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
    Suzuki H; Watanabe Y; Kumagai H; Shuto H
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe plus simvastatin cardiovascular outcomes study program.
    Padial LR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for cardiovascular disease in children on chronic hemodialysis - Uremia related (non-traditional) risk factors, part II.
    Šulović LS
    Vojnosanit Pregl; 2017 Jan; 74(1):54-8. PubMed ID: 29350892
    [No Abstract]   [Full Text] [Related]  

  • 19. [How sure is the combined lipid lowering?].
    Schäfer J
    MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
    [No Abstract]   [Full Text] [Related]  

  • 20. Can dialysis modality influence cardiovascular outcome?
    Shroff R
    Pediatr Nephrol; 2012 Nov; 27(11):2001-2005. PubMed ID: 22660957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.